TY - JOUR
T1 - Bone engineering by phosphorylated-pullulan and β-TCP composite
AU - Takahata, Tomohiro
AU - Okihara, Takumi
AU - Yoshida, Yasuhiro
AU - Yoshihara, Kumiko
AU - Shiozaki, Yasuyuki
AU - Yoshida, Aki
AU - Yamane, Kentaro
AU - Watanabe, Noriyuki
AU - Yoshimura, Masahide
AU - Nakamura, Mariko
AU - Irie, Masao
AU - Van Meerbeek, Bart
AU - Tanaka, Masato
AU - Ozaki, Toshifumi
AU - Matsukawa, Akihiro
N1 - Publisher Copyright:
© 2015 IOP Publishing Ltd.
PY - 2015/11/20
Y1 - 2015/11/20
N2 - A multifunctional biomaterial with the capacity bond to hard tissues, such as bones and teeth, is a real need for medical and dental applications in tissue engineering and regenerative medicine. Recently, we created phosphorylated-pullulan (PPL), capable of binding to hydroxyapatite in bones and teeth. In the present study, we employed PPL as a novel biocompatible material for bone engineering. First, an in vitro evaluation of the mechanical properties of PPL demonstrated both PPL and PPL/β-TCP composites have higher shear bond strength than materials in current clinical use, including polymethylmethacrylate (PMMA) cement and α-tricalcium phosphate (TCP) cement, Biopex-R. Further, the compressive strength of PPL/β-TCP composite was significantly higher than Biopex-R. Next, in vivo osteoconductivity of PPL/β-TCP composite was investigated in a murine intramedular injection model. Bone formation was observed 5 weeks after injection of PPL/β-TCP composite, which was even more evident at 8 weeks; whereas, no bone formation was detected after injection of PPL alone. We then applied PPL/β-TCP composite to a rabbit ulnar bone defect model and observed bone formation comparable to that induced by Biopex-R. Implantation of PPL/β-TCP composite induced new bone formation at 4 weeks, which was remarkably evident at 8 weeks. In contrast, Biopex-R remained isolated from the surrounding bone at 8 weeks. In a pig vertebral bone defect model, defects treated with PPL/β-TCP composite were almost completely replaced by new bone; whereas, PPL alone failed to induce bone formation. Collectively, our results suggest PPL/β-TCP composite may be useful for bone engineering.
AB - A multifunctional biomaterial with the capacity bond to hard tissues, such as bones and teeth, is a real need for medical and dental applications in tissue engineering and regenerative medicine. Recently, we created phosphorylated-pullulan (PPL), capable of binding to hydroxyapatite in bones and teeth. In the present study, we employed PPL as a novel biocompatible material for bone engineering. First, an in vitro evaluation of the mechanical properties of PPL demonstrated both PPL and PPL/β-TCP composites have higher shear bond strength than materials in current clinical use, including polymethylmethacrylate (PMMA) cement and α-tricalcium phosphate (TCP) cement, Biopex-R. Further, the compressive strength of PPL/β-TCP composite was significantly higher than Biopex-R. Next, in vivo osteoconductivity of PPL/β-TCP composite was investigated in a murine intramedular injection model. Bone formation was observed 5 weeks after injection of PPL/β-TCP composite, which was even more evident at 8 weeks; whereas, no bone formation was detected after injection of PPL alone. We then applied PPL/β-TCP composite to a rabbit ulnar bone defect model and observed bone formation comparable to that induced by Biopex-R. Implantation of PPL/β-TCP composite induced new bone formation at 4 weeks, which was remarkably evident at 8 weeks. In contrast, Biopex-R remained isolated from the surrounding bone at 8 weeks. In a pig vertebral bone defect model, defects treated with PPL/β-TCP composite were almost completely replaced by new bone; whereas, PPL alone failed to induce bone formation. Collectively, our results suggest PPL/β-TCP composite may be useful for bone engineering.
KW - bone formation
KW - phosphorylated-pullulan
KW - β-TCP
UR - http://www.scopus.com/inward/record.url?scp=84950129925&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84950129925&partnerID=8YFLogxK
U2 - 10.1088/1748-6041/10/6/065009
DO - 10.1088/1748-6041/10/6/065009
M3 - Article
C2 - 26586655
AN - SCOPUS:84950129925
SN - 1748-6041
VL - 10
JO - Biomedical Materials (Bristol)
JF - Biomedical Materials (Bristol)
IS - 6
M1 - 065009
ER -